Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster II
Hematology Disease Topics & Pathways:
Adult, Diseases, Marginal Zone Lymphoma, Non-Hodgkin Lymphoma, Lymphoid Malignancies, Study Population
Method: We used the population-based Surveillance, Epidemiology, and End Results (SEER)-18 database. We included adult patients with NMZL diagnosed between 2000-2017 who were 18-84 years old at the time of diagnosis. We excluded patients with a history of malignancy prior to NMZL, those with missing survival times and those with central nervous system involvement. Patients were divided into two cohorts based on period of diagnosis (era-1: 2000-2008, and era-2: 2009-2017). Relative survival (RS) was estimated using the Pohar-Perme method, and the difference between RS distributions was tested using a log-rank-type test. Relative survival was modeled using Poisson regression where the effect of follow-up time was included as restricted cubic spline with 5 knots. All tests of differences were performed at a two-sided alpha of 0.05.
Results: We included 5,355 patients with NMZL. Table 1 shows the baseline characteristics. The median age at diagnosis was 66 years (IQR = 56-74 years). Most patients were non-Hispanic White (73%) with advanced stage at diagnosis (stage III-IV, 63%). The 5-year RS (unadjusted) was 84% (95% CI = 82% - 86%) for patients diagnosed in era-1 and 86% (95% CI = 84% - 89%) for patients diagnosed in era-2 (log-rank-type p = 0.07). Figure 1A shows cumulative RS, and Figure 1B shows the trend in 5-year RS over the study period (including model-based and empirical estimates). In our multivariable Poisson regression model for RS, the period of diagnosis, age, sex, median household income, and stage at diagnosis were significant predictors of excess mortality (Table 2). Patients in era-2 had significantly lower excess mortality [excess hazard ratio (EHR) = 0.76, 95% CI=0.62-0.93], while excess mortality significantly increased with age over 65 years [EHR = 2.09, 95% CI=1.70-2.56], male sex [EHR = 1.38, 95% CI=1.13-1.68], and advanced stage at diagnosis [EHR = 1.96, 95% CI=1.47-2.63].
Conclusion: There has been a significant improvement in RS in the most recent era for patients with NMZL in the United States after adjusting for differences in age, sex, race/ethnicity, income, and stage at diagnosis. This improvement at the population level is likely reflective of the improvement in supportive care and advances in the NMZL treatment including identification of better tolerable chemotherapy regimens and novel agents.
Disclosures: Epperla: Verastem Oncology: Speakers Bureau; Pharmacyclics: Honoraria.
See more of: Oral and Poster Abstracts